As the sole DM-only patient advocacy organization in the US, MDF plays an important role in the search for treatments, in improving care, and ensuring that the DM community voice is heard as we move forward. To continue to meet our obligations to our community and to our mission of Care and a Cure, MDF held its annual strategic planning offsite last weekend.
Several scientists have published the results of important DM research. Dr. Katharine Hagerman, PhD, Research Assistant at Stanford University, has provided MDF with lay summaries of some of this research.
The MDF Fund-a-Fellow program is designed to help attract new researchers to the DM field, increasing the knowledge and science available regarding myotonic dystrophy. We are pleased to announce this year’s award recipients!
Isis Pharmaceuticals, Inc. has initiated a Phase I/II trial for ISIS-DMPKrx in patients affected by myotonic dystrophy type 1 (DM1).
In 2013, MDF launched a significant effort to increase the number of support groups for families living with DM, and we now have 14 groups across the US and Canada. Join us in celebrating the people who have brought these groups to life!